Teva Pharmaceutical Industries (NYSE:TEVA) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 3.6% this past week
Teva completes $40b purchase of Allergan generics arm | The Times of Israel
Teva shares tumble after "challenging" Q4, FY17 - MassDevice